Key result
Prostate cancer therapies, including androgen deprivation therapy and novel antiandrogens, carry a significant risk of cardiovascular complications that require careful screening and management.
Why the study?
Many systemic prostate cancer therapies carry a risk of cardiovascular complications that can pose a higher mortality threat than the cancer itself.
Do prostate cancer therapies increase the risk of cardiovascular complications in men with prostate cancer?
Do prostate cancer therapies increase the risk of cardiovascular complications in men with prostate cancer?
This review highlights the significant cardiovascular toxicities associated with prostate cancer treatments, emphasizing the need for cardio-oncology screening and management.
May warrant cardio-oncology screening during prostate cancer therapy; leaves open optimal strategies pending prospective trials.
Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. In recent years, numerous novel therapeutics that improve survival and ameliorate disease control have been approved. Currently, the systemic treatment for prostate neoplasm consists of hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, targeted therapy, and supportive agents (e.g., related to bone health). Unfortunately, many of them carry a risk of cardiovascular complications, which occasionally pose a higher mortality threat than cancer itself. This article provides a unique and comprehensive overview of the prevalence and possible mechanisms of cardiovascular toxicities of all PC therapies, including state-of-the-art antineoplastic agents. Additionally, this article summarizes available recommendations regarding screening and prevention of the most common cardiac complications among patients with advanced cancer disease.
No takes yet. Share an insight, caveat, or question.
Wilk et al. (2020) conducted a review in Prostate cancer. Prostate cancer treatments (ADT, antiandrogens, chemotherapy, immunotherapy) was evaluated on Cardiovascular complications. Prostate cancer therapies, including androgen deprivation therapy and novel antiandrogens, carry a significant risk of cardiovascular complications that require careful screening and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: